Jawbone damage was very rare at standard doses of bone loss medicines, with little or no clear difference between the groups compared. Medscape reported on a study presented at a 2026 bone health meeting in Boston. It compared medicines that slow bone loss in people taking these treatments. These included Selective Estrogen Receptor Modulators, medicines that act like estrogen in some tissues and block it in others. The other groups were Bisphosphonates and Denosumab, two types of medicine that slow bone breakdown. The study focused on a rare problem where jawbone tissue dies. The supplied report describes the risk as very low at standard doses. It does not give exact case counts or rates for each group. It also leaves out the number of people studied and their ages. So, this excerpt cannot show how many people out of 1,000 had the problem. The article also puts this risk beside the benefits of preventing broken bones. It notes that about half of women will have a break linked to weak bones during their lives. These medicines can lower fracture risk by up to 40% with routine use in suitable groups. That figure is background context, not a result from this jawbone comparison. For BioSocial members, this offers context for tracking treatment experiences alongside Bone Mineral Density results. Comparing medicine names, doses, time on treatment, and side effects can make community notes more useful. Those personal records are not the same as measuring a rare risk. What changes in your bone health numbers or treatment experience have you tracked over time?